OBJECTIVE

To evaluate the association between irregular sleep duration and incident diabetes in a U.K. population over 7 years of follow-up.

RESEARCH DESIGN AND METHODS

Among 84,421 UK Biobank participants (mean age 62 years) who were free of diabetes at the time of providing accelerometer data in 2013–2015 and prospectively followed until May 2022, sleep duration variability was quantified by the within-person SD of 7-night accelerometer-measured sleep duration. We used Cox proportional hazard models to estimate hazard ratios (HRs) for incident diabetes (identified from medical records, death register, and/or self-reported diagnosis) according to categories of sleep duration SD.

RESULTS

There were 2,058 incident diabetes cases over 622,080 person-years of follow-up. Compared with sleep duration SD ≤ 30 min, the HR (95% CI) was 1.15 (0.99, 1.33) for 31–45 min, 1.28 (1.10, 1.48) for 46–60 min, 1.54 (1.32, 1.80) for 61–90 min, and 1.59 (1.33, 1.90) for ≥91 min, after adjusting for age, sex, and race. We found a nonlinear relationship (P nonlinearity 0.0002), with individuals with a sleep duration SD of >60 vs. ≤60 min having 34% higher diabetes risk (95% CI 1.22, 1.47). Further adjustment for lifestyle, comorbidities, environmental factors, and adiposity attenuated the association (HR comparing sleep duration SD of >60 vs. ≤60 min: 1.11; 95% CI 1.01, 1.22). The association was stronger among individuals with lower diabetes polygenic risk score (PRS; P interaction ≤ 0.0264) and longer sleep duration (P interaction ≤ 0.0009).

CONCLUSIONS

Irregular sleep duration was associated with higher diabetes risk, particularly in individuals with a lower diabetes PRS and longer sleep duration.

With more than 537 million prevalent cases and 6.7 million annual attributable deaths, type 2 diabetes is a rapidly growing but potentially preventable chronic disease worldwide (1). Identifying novel, modifiable diabetes risk factors could help in developing new interventions that reduce diabetes burden. The circadian timing system, consisting of the central brain clock and peripheral clocks in organs/tissues, regulates daily rhythmicity of glucose tolerance and insulin sensitivity (2). Misalignment between the circadian timing system and sleep-wake cycles due to behavioral, environmental, or genetic factors could result in insulin resistance and diabetes development (2).

Sleep duration, sleep quality, and other sleep disturbances (e.g., related to shift work) have been linked to diabetes risk in prior studies (3–5). Emerging evidence suggests that sleep irregularity/variability, which characterizes daily variations in sleep duration or timing, may be a novel risk factor for metabolic health independent of sleep quantity and quality. Irregular sleep may be a marker of habitual exposure to circadian disruption due to modern lifestyle (e.g., increased night activities) and environmental factors (e.g., noise, light at night). Irregular sleep may shift circadian phase from one night to another and disrupt circadian rhythms (6), leading to glucose dysregulation (7), metabolic syndrome (8), and, over time, an increased risk of insulin resistance and diabetes. There are multiple ways of measuring irregular sleep (9). Operationalized as within-person SD of sleep measures across multiple consecutive nights (10), prior cross-sectional studies have linked less regular sleep with metabolic abnormalities and diabetes (8,10). However, the only prospective cohort study to date found no significant association between sleep irregularity and incident diabetes in 2,107 Hispanics/Latinos, using the SD or the sleep regularity index (10,11). Given the modest sample size of this study, larger prospective studies are needed to determine whether irregular sleep is associated with risk for incident diabetes (10) and whether this association varies by demographic or other sleep-related factors.

It remains unknown whether irregular sleep duration, a potentially modifiable behavioral factor, interacts with genetic susceptibility to influence diabetes risk. Given the associations of irregular sleep duration with key diabetes precursors including obesity, inflammation, and metabolic syndrome, it is possible that, because of shared genetic factors, irregular sleep would be more strongly linked to incident diabetes risk in people with a low genetic predisposition to diabetes when compared with people with a high genetic predisposition to diabetes (8,12,13).

In this study, we evaluated the prospective association between accelerometer-measured irregular sleep duration and diabetes risk in a large cohort of U.K. adults. A priori, we hypothesized that people with greater irregular sleep duration would be at higher risk of incident diabetes and that this association would be stronger among participants with a high genetic risk for diabetes or short/long sleep duration.

Study Design, Setting, and Participants

The UK Biobank (UKB) is an ongoing large community-based prospective cohort study. As of July 2023, the UKB involves 502,364 participants who were 40–69 years old during enrollment in 2006–2010 (14). Participants were recruited from a pool of 9.2 million individuals registered with the National Health Service, representing diverse sociodemographic backgrounds across the U.K. All participants provided e-Consent and attended a baseline visit, which included a touch-screen questionnaire, a computer-assisted interview about sociodemographic information, family history, psychosocial factors, and lifestyle; physical measurements; and blood sample collection (14). Data collection on some baseline measures was repeated for smaller subsamples of participants up to four times. Genotyping and standard biochemical assays were performed at baseline for the entire cohort. Information on health outcomes is routinely collected via linkages to multiple national databases, such as Hospital Episode Statistics data and death registry records.

Between 2013 and 2015, a subsample of 236,519 UKB participants with a valid e-mail address were invited to participate in an accelerometer study (15). With a response rate of 44%, 103,628 participants accepted the invitation and completed the accelerometer measurement. Among 91,451 participants with good quality accelerometer data, we excluded 3,604 participants with prevalent diabetes at the time of accelerometry. We further excluded participants with less than five nights of sleep duration data (n = 2,924), anomalous values (those with sleep duration SD >4 h; n = 34), or missing sleep duration SD values (n = 465), or those lost to medical follow-up before the accelerometer study (n = 3), leaving 84,421 participants for analysis (Supplementary Fig. 1).

Sleep Assessment

Participants wore Axivity AX3 (Open Lab, Newcastle University), a waterproof triaxial accelerometer, on their dominant wrist for 7 days (15). The Axivity AX3 has a stable inter- and intradevice variability when measuring movement, and, in multiaxis shaking tests, it performs slightly better than the GENEActiv accelerometer, a commonly used accelerometer in health research (15,16). Sleep duration variability was defined as the SD of accelerometer-measured sleep duration in hours across main sleep periods. A previous study in UKB (17) derived the mean and SD of accelerometer-measured sleep duration across all days, using an R package, GGIR version 1.5.12 (18). In a validation study among 50 participants, the C statistic for the GGIR package to accurately detect accelerometer-measured sleep period time windows was >0.8 when compared with polysomnography data (19). In the main analysis, we evaluated sleep duration SD across all days both continuously and in categories as ≤30, 31–45, 46–60, 61–90, and ≥91 min.

We applied the same approach as the previous study (17), using GGIR 3.0.9 (20,21), to derive additional accelerometer-based sleep variables for the main sleep period, including sleep onset timing SD across all days and weekdays, mean weekday sleep duration, and weekday sleep duration SD. Additionally, sleep apnea was identified through medical records and self-reports. Insomnia symptoms, chronotype, and daytime sleepiness were self-reported at UKB baseline (Supplementary Table 1).

Incident Diabetes

In the UKB, the first occurrence of diabetes is identified using a standard algorithm, by mapping ICD-10 code E11 (i.e., noninsulin-dependent diabetes mellitus) to participants’ health-related records, including their primary care data, hospital inpatient data, and death register records (22). Additionally, at the UKB assessment center visits, participants self-reported doctor-diagnosed health conditions. A UKB nurse conducted a verbal interview to verify responses, and, when uncertain, a doctor further assessed and classified the self-reported conditions. The algorithm also incorporated verified self-reports of doctor-diagnosed diabetes. This algorithm has been utilized successfully in prior studies to identify incident diabetes cases (23–25). Incident diabetes was defined as diabetes occurring after the accelerometer study end date.

Polygenic Risk Score for Diabetes

Genotyping was conducted using UKB Axiom (90% of participants) and UK Biobank Lung Exome Variant Evaluation (10% of participants) arrays, directly targeting ∼800,000 genetic markers. An additional 96 million genetic variants were derived using imputation. Rigorous quality control confirmed the high reliability and accuracy of imputed genetic variants (26). In UKB, a Bayesian approach was used to create polygenic risk score (PRS) for diabetes from the meta-analysis of external (non-UKB) genome-wide association studies, and a principal component–based ancestry centering technique was implemented to normalize the diabetes PRS distribution across all ancestries (27,28). We categorized participants according to the PRS as having low (first tertile), intermediate (second tertile), or high (third tertile) genetic risk for diabetes.

Statistical Analysis

We used mean (SD) and percentage to report the distributions for a wide range of covariates across sleep duration SD categories (Supplementary Covariate Assessment and Supplementary Table 1). Cox proportional hazards model was used to estimate the hazard ratio (HR) for the association between sleep duration SD and incident diabetes. Person-time at risk accrued from the accelerometer end-of-wear date up to the onset of diabetes, lost to follow-up, death, or the censoring date (31 May 2022), whichever came first. The proportional hazards assumption was tested by including an interaction term between the exposure and time of follow-up, and no violation of this assumption was detected (P interaction ≥ 0.8608).

We fitted three models. Because comorbidities and adiposity may be a consequence of irregular sleep duration, we evaluated these covariates in separate models (models 2 and 3) to avoid potential overadjustment. In model 1, we included age, sex, and race. In model 2, we further adjusted for Townsend deprivation index, home area type, education, occupation/shift work, family history of diabetes, smoking, physical activity, healthy diet score, coffee or tea intake, alcohol consumption, average noise level, fine particulate matter (PM2.5), and season, along with heart failure, dyslipidemia, hypertension, depression, and osteoarthritis. In model 3, we added BMI and waist circumference. We conducted four sensitivity analyses: 1) We assessed whether the association between sleep duration SD and diabetes risk was independent of other sleep-related factors (sleep apnea, insomnia, mean sleep duration, chronotype, daytime sleepiness, and sleep onset timing SD). 2) To address potential reverse causation, we excluded incident diabetes cases from the first two years of follow-up. 3) To explore whether the association observed for 7-day sleep duration variability was driven by weekday-weekend differences (e.g., as may occur with social jetlag), we repeated the main analysis using sleep duration SD restricted to data collected only for weekdays. 4) As diabetes tended to be underdiagnosed in U.K. during the pandemic (29), we divided the study follow-up into three mutually exclusive periods: the first 2 years of follow-up, from post 2-year follow-up to 11 March 2020 (coronavirus disease 2019 pandemic start date), and after 11 March 2020 (pandemic period). In all analyses, reference group was the most regular sleep duration group (sleep duration SD ≤30 min). We evaluated both the linear trend by modeling sleep duration SD as a continuous variable and potential nonlinearity using restricted cubic splines with three knots at 10th, 50th, and 90th percentiles. Statistical significance of nonlinearity was assessed by a likelihood ratio test comparing the fit of the linear model to the spline model. As our findings suggested a nonlinear relationship, we conducted a post hoc analysis using the nonparametric locally weighted scatterplot smoothing method (30) to identify 62 min as the point of notable curvilinear change. For simplicity, we used the dichotomized sleep duration SD at the 60-min cutoff in further analyses.

In the gene-sleep interaction analysis, we fitted multivariable models as described above, with additional adjustment for the first 10 ancestry principal components to address population stratification. We used an interaction term between PRS and sleep duration SD to evaluate the effect modification on a multiplicative scale. Secondarily, we implemented relative excess risk due to interaction to assess potential effect modification on an additive scale. In parallel, we considered family history of diabetes a second genetic risk indicator for diabetes and repeated the gene-sleep interaction analysis. Participants with a family history of diabetes had a significantly higher PRS (Supplementary Fig. 2). Further, we formulated a composite genetic indicator combining both PRS and family history, following a previous study (31). Participants with both a PRS in the upper tertile and a family history of diabetes were categorized as having a high diabetes genetic risk, while others were categorized as having a low genetic risk. We restricted analyses involving PRS to participants who identified themselves as White.

We performed subgroup analysis, using models 1 and 3, according to accelerometer-measured sleep duration (<7, 7–8, >8 h). We further examined subgroup associations by age at baseline, sex, race, BMI, Townsend deprivation index, occupation/shift work, insomnia symptoms, and chronotype. We assessed the statistical significance of effect modification on a multiplicative scale as described above.

Lastly, we estimated the population attributable risk (PAR) to quantify the proportion of diabetes cases in the population that could be prevented if sleep duration SD was reduced from >60 min to ≤60 min, assuming a causal link between sleep duration SD and diabetes and that the effect of sleep duration SD is completely reversable. We processed and visualized data with Python, and conducted statistical analyses using SAS version 9.4 (Cary, NC).

At the accelerometer study, participants were, on average, aged 62 (SD 8) years, 57% were female, 97% were White, 45% had a college degree, and 50% were employed with nonshift work jobs. Approximately 29% of participants had a sleep duration SD of >60 min (Supplementary Fig. 3). Participants with higher sleep duration SD were younger and more likely to be female, shift workers, or current smokers; report definite “evening” chronotype; have higher Townsend deprivation index (indicating poorer socioeconomic status), higher BMI, and shorter mean sleep duration; and were less likely to be White (Table 1). Family history of diabetes and depression were more prevalent among participants with higher sleep duration SD. Participants with higher sleep duration SD tended to have either short or long mean sleep duration (with more participants toward shorter sleep duration), displaying an asymmetrical U-shaped pattern (P nonlinearity < 0.0001) (Supplementary Fig. 4).

Table 1

Participants characteristics at baseline, n = 84,421

Sleep duration SD in minutes
Totaln = 84,421≤30n = 12,69831–45n = 25,83946–60n = 21,74061–90n = 16,023≥91n = 8,121
Age, years 62.3 (7.8) 63.6 (7.7) 63 (7.8) 62.2 (7.8) 61.4 (7.7) 60.5 (8) 
Male, % 42.6 46.7 43.6 41.5 39.4 42.0 
White race, % 97.1 98.3 97.8 97.1 96.4 94.9 
Townsend deprivation index* −1.8 (2.8) −2 (2.6) −1.9 (2.7) −1.8 (2.8) −1.6 (2.9) −1.4 (3) 
Rural home area, % 8.3 9.1 8.5 8.2 7.6 7.7 
College or university degree, %* 44.8 45.8 45.9 44.7 42.8 44.0 
Current occupation/shift work, %*       
 Employed, never/rarely shift work 50.1 45.5 48.9 51.4 53.0 51.9 
 Employed, sometimes/usually/always shift work 7.5 5.2 5.8 7.0 9.8 12.9 
 Retired/other 42.4 49.3 45.2 41.6 37.2 35.2 
Family history of diabetes, %* 21.1 20.2 20.5 21.6 21.8 22.3 
Diabetes PRS −0.2 (1) −0.2 (0.9) −0.2 (1) −0.2 (1) −0.2 (0.9) −0.2 (1) 
BMI, kg/m2* 26.5 (4.4) 26.1 (4.1) 26.2 (4.2) 26.6 (4.3) 26.9 (4.5) 27.1 (4.8) 
Waist circumference, cm* 87.7 (12.6) 87.3 (12.3) 87.3 (12.4) 87.8 (12.5) 88.2 (13) 88.7 (13.2) 
Smoking status, %*       
 Current 6.5 5.4 5.7 6.4 7.7 8.7 
 Never 57.9 59.3 58.6 57.9 56.4 57.0 
 Previous 35.6 35.3 35.7 35.7 36.0 34.3 
Moderate-vigorous physical activity, min/day 42 (34.5) 44.9 (35.7) 43.4 (34.9) 41.3 (34) 39.4 (33.4) 40 (34.5) 
Healthy diet score* 3.1 (1.2) 3.2 (1.2) 3.2 (1.2) 3.1 (1.2) 3.1 (1.2) 3.1 (1.3) 
Coffee/tea intake, cups per day* 3.8 (4.2) 3.9 (4) 3.9 (4.2) 3.8 (4.3) 3.8 (4.3) 3.8 (4.3) 
Alcohol consumption, %*       
 Current 94.5 94.6 94.7 94.8 94.1 93.4 
 Never 2.9 2.9 2.8 2.7 2.9 3.3 
 Previous 2.7 2.5 2.5 2.5 3.0 3.3 
Average 24-h noise level, dB 56 (4.2) 55.9 (4.1) 55.9 (4.1) 56 (4.2) 56.1 (4.2) 56 (4.2) 
PM2.5, µg/m3 9.9 (1) 9.8 (1) 9.9 (1) 9.9 (1) 9.9 (1) 9.9 (1) 
Accelerometer wear season, %       
 Autumn 29.9 30.5 30.1 30.1 29.1 29.4 
 Summer 26.1 25.8 26.4 25.9 26.6 25.8 
 Spring 22.6 22.5 22.5 22.9 22.2 22.8 
 Winter 21.4 21.2 21.1 21.2 22.1 22.0 
Heart failure, % 0.6 0.6 0.6 0.6 0.6 0.5 
Dyslipidemia, % 17.2 18.1 17.6 17.1 16.8 15.9 
Hypertension, % 25.3 25.3 25.6 25.0 25.6 24.8 
Self-reported depression, %* 34.0 30.6 32.4 34.9 36.9 36.8 
Osteoarthritis, % 16.2 16.4 16.4 15.9 16.5 15.5 
Sleep apnea, % 0.9 0.5 0.8 0.9 1.0 1.2 
Insomnia, %*       
 Never/rarely 25.3 25.2 25.4 25.3 25.1 25.9 
 Sometimes 47.8 49.0 47.9 48.1 46.7 47.0 
 Usually 26.8 25.8 26.6 26.6 28.1 27.1 
Accelerometer measured mean sleep duration 7.3 (0.8) 7.5 (0.7) 7.4 (0.8) 7.4 (0.8) 7.3 (0.8) 6.7 (0.9) 
Chronotype, %*       
 Definitely a “morning” person 23.3 22.9 23.7 23.5 23.1 23.0 
 More a “morning” than an “evening” person 34.1 36.2 34.9 34.5 32.3 31.1 
 Intermediate 10.0 10.8 10.3 9.7 9.6 9.4 
 More an “evening” than a “morning” person 24.5 23.7 24.0 24.5 25.1 26.1 
 Definitely an “evening” person 8.1 6.5 7.1 7.9 10.0 10.5 
Daytime sleepiness, %*       
 All of the time/often 2.2 1.7 2.1 2.3 2.4 2.6 
 Never/rarely 78.7 79.3 79.2 78.6 77.8 78.1 
 Sometimes 19.1 19.0 18.8 19.1 19.8 19.3 
Sleep onset timing SD 1 (0.7) 0.7 (0.5) 0.8 (0.5) 1 (0.6) 1.2 (0.8) 1.5 (1.3) 
Sleep duration SD in minutes
Totaln = 84,421≤30n = 12,69831–45n = 25,83946–60n = 21,74061–90n = 16,023≥91n = 8,121
Age, years 62.3 (7.8) 63.6 (7.7) 63 (7.8) 62.2 (7.8) 61.4 (7.7) 60.5 (8) 
Male, % 42.6 46.7 43.6 41.5 39.4 42.0 
White race, % 97.1 98.3 97.8 97.1 96.4 94.9 
Townsend deprivation index* −1.8 (2.8) −2 (2.6) −1.9 (2.7) −1.8 (2.8) −1.6 (2.9) −1.4 (3) 
Rural home area, % 8.3 9.1 8.5 8.2 7.6 7.7 
College or university degree, %* 44.8 45.8 45.9 44.7 42.8 44.0 
Current occupation/shift work, %*       
 Employed, never/rarely shift work 50.1 45.5 48.9 51.4 53.0 51.9 
 Employed, sometimes/usually/always shift work 7.5 5.2 5.8 7.0 9.8 12.9 
 Retired/other 42.4 49.3 45.2 41.6 37.2 35.2 
Family history of diabetes, %* 21.1 20.2 20.5 21.6 21.8 22.3 
Diabetes PRS −0.2 (1) −0.2 (0.9) −0.2 (1) −0.2 (1) −0.2 (0.9) −0.2 (1) 
BMI, kg/m2* 26.5 (4.4) 26.1 (4.1) 26.2 (4.2) 26.6 (4.3) 26.9 (4.5) 27.1 (4.8) 
Waist circumference, cm* 87.7 (12.6) 87.3 (12.3) 87.3 (12.4) 87.8 (12.5) 88.2 (13) 88.7 (13.2) 
Smoking status, %*       
 Current 6.5 5.4 5.7 6.4 7.7 8.7 
 Never 57.9 59.3 58.6 57.9 56.4 57.0 
 Previous 35.6 35.3 35.7 35.7 36.0 34.3 
Moderate-vigorous physical activity, min/day 42 (34.5) 44.9 (35.7) 43.4 (34.9) 41.3 (34) 39.4 (33.4) 40 (34.5) 
Healthy diet score* 3.1 (1.2) 3.2 (1.2) 3.2 (1.2) 3.1 (1.2) 3.1 (1.2) 3.1 (1.3) 
Coffee/tea intake, cups per day* 3.8 (4.2) 3.9 (4) 3.9 (4.2) 3.8 (4.3) 3.8 (4.3) 3.8 (4.3) 
Alcohol consumption, %*       
 Current 94.5 94.6 94.7 94.8 94.1 93.4 
 Never 2.9 2.9 2.8 2.7 2.9 3.3 
 Previous 2.7 2.5 2.5 2.5 3.0 3.3 
Average 24-h noise level, dB 56 (4.2) 55.9 (4.1) 55.9 (4.1) 56 (4.2) 56.1 (4.2) 56 (4.2) 
PM2.5, µg/m3 9.9 (1) 9.8 (1) 9.9 (1) 9.9 (1) 9.9 (1) 9.9 (1) 
Accelerometer wear season, %       
 Autumn 29.9 30.5 30.1 30.1 29.1 29.4 
 Summer 26.1 25.8 26.4 25.9 26.6 25.8 
 Spring 22.6 22.5 22.5 22.9 22.2 22.8 
 Winter 21.4 21.2 21.1 21.2 22.1 22.0 
Heart failure, % 0.6 0.6 0.6 0.6 0.6 0.5 
Dyslipidemia, % 17.2 18.1 17.6 17.1 16.8 15.9 
Hypertension, % 25.3 25.3 25.6 25.0 25.6 24.8 
Self-reported depression, %* 34.0 30.6 32.4 34.9 36.9 36.8 
Osteoarthritis, % 16.2 16.4 16.4 15.9 16.5 15.5 
Sleep apnea, % 0.9 0.5 0.8 0.9 1.0 1.2 
Insomnia, %*       
 Never/rarely 25.3 25.2 25.4 25.3 25.1 25.9 
 Sometimes 47.8 49.0 47.9 48.1 46.7 47.0 
 Usually 26.8 25.8 26.6 26.6 28.1 27.1 
Accelerometer measured mean sleep duration 7.3 (0.8) 7.5 (0.7) 7.4 (0.8) 7.4 (0.8) 7.3 (0.8) 6.7 (0.9) 
Chronotype, %*       
 Definitely a “morning” person 23.3 22.9 23.7 23.5 23.1 23.0 
 More a “morning” than an “evening” person 34.1 36.2 34.9 34.5 32.3 31.1 
 Intermediate 10.0 10.8 10.3 9.7 9.6 9.4 
 More an “evening” than a “morning” person 24.5 23.7 24.0 24.5 25.1 26.1 
 Definitely an “evening” person 8.1 6.5 7.1 7.9 10.0 10.5 
Daytime sleepiness, %*       
 All of the time/often 2.2 1.7 2.1 2.3 2.4 2.6 
 Never/rarely 78.7 79.3 79.2 78.6 77.8 78.1 
 Sometimes 19.1 19.0 18.8 19.1 19.8 19.3 
Sleep onset timing SD 1 (0.7) 0.7 (0.5) 0.8 (0.5) 1 (0.6) 1.2 (0.8) 1.5 (1.3) 

The table was constructed after missing values had been filled in; most covariates had <1% missing, none exceeding 7.5%. For continuous covariates, which are those not indicated by a “%” sign, the mean and SD, in parentheses, are reported.

*

Covariate assessment year is, on average, 5.1 years before the end date of the accelerometer study.

Healthy diet score was adopted from the American Heart Association guidelines and was created following Rutten-Jacobs et al. (32).

Prospective Association Between Sleep Duration SD and Diabetes Risk

During 622,080 person-years of follow-up (median 7.5 years), 2,058 participants developed diabetes. In model 1, when compared with the participants with ≤30 min of sleep duration SD, the HR (95% CI) for diabetes risk was 1.15 (0.99, 1.33) for 31–45 min, 1.28 (1.10, 1.48) for 46–60 min, 1.54 (1.32, 1.80) for 61–90 min, and 1.59 (1.33, 1.90) for ≥91 min of sleep duration SD (P trend < 0.0001) (Table 2). This association was attenuated in model 2 with adjustment for additional socioeconomic factors, metabolic comorbidities, and depression (P trend = 0.0010), and was further attenuated in model 3 when we additionally controlled for BMI and waist circumference (P trend = 0.0688).

Table 2

Prospective associations between sleep duration SD and risk of incident diabetes, n = 84,421

ExposureIncident diabetes/person-yearsHR (95% CI)Model 1HR (95% CI)Model 2HR (95% CI)Model 3§
Sleep duration SD     
 ≤30 min 262/93,467 Reference Reference Reference 
 31–45 min 588/190,499 1.15 (0.99, 1.33) 1.10 (0.95, 1.27) 1.08 (0.93, 1.25) 
 46–60 min 529/160,371 1.28 (1.10, 1.48) 1.15 (1.00, 1.34) 1.10 (0.94, 1.27) 
 61–90 min 446/117,928 1.54 (1.32, 1.80) 1.30 (1.12, 1.52) 1.20 (1.03, 1.40) 
 ≥91 min 233/59,815 1.59 (1.33, 1.90) 1.32 (1.10, 1.57) 1.16 (0.97, 1.39) 
Sleep duration SD (per 1 h SD) 2,058/622,080 1.24 (1.15, 1.34) 1.14 (1.06, 1.24) 1.08 (0.99, 1.17) 
P trend  <0.0001 0.0010 0.0688 
P nonlinearity*  0.0002 0.0544 0.2151 
Dichotomized sleep duration SD     
 ≤60 min 1,379/444,338 Reference Reference Reference 
 >60 min 679/177,743 1.34 (1.22, 1.47) 1.19 (1.08, 1.30) 1.11 (1.01, 1.22) 
 PAR % (95% CI)  8.3 (5.7, 10.8) 3.1 (1.4, 4.7) 1.1 (0.1, 2.1) 
ExposureIncident diabetes/person-yearsHR (95% CI)Model 1HR (95% CI)Model 2HR (95% CI)Model 3§
Sleep duration SD     
 ≤30 min 262/93,467 Reference Reference Reference 
 31–45 min 588/190,499 1.15 (0.99, 1.33) 1.10 (0.95, 1.27) 1.08 (0.93, 1.25) 
 46–60 min 529/160,371 1.28 (1.10, 1.48) 1.15 (1.00, 1.34) 1.10 (0.94, 1.27) 
 61–90 min 446/117,928 1.54 (1.32, 1.80) 1.30 (1.12, 1.52) 1.20 (1.03, 1.40) 
 ≥91 min 233/59,815 1.59 (1.33, 1.90) 1.32 (1.10, 1.57) 1.16 (0.97, 1.39) 
Sleep duration SD (per 1 h SD) 2,058/622,080 1.24 (1.15, 1.34) 1.14 (1.06, 1.24) 1.08 (0.99, 1.17) 
P trend  <0.0001 0.0010 0.0688 
P nonlinearity*  0.0002 0.0544 0.2151 
Dichotomized sleep duration SD     
 ≤60 min 1,379/444,338 Reference Reference Reference 
 >60 min 679/177,743 1.34 (1.22, 1.47) 1.19 (1.08, 1.30) 1.11 (1.01, 1.22) 
 PAR % (95% CI)  8.3 (5.7, 10.8) 3.1 (1.4, 4.7) 1.1 (0.1, 2.1) 
*

The test for nonlinearity was a likelihood ratio test comparing the models with versus without the restricted cubic splines. Continuous exposure was included in spline models.

Model 1 adjusted for age in months, sex, and race.

Model 2 adjusted for covariates in model 1 along with Townsend deprivation index, home area type, education, occupation/shift work, family history of diabetes, smoking, physical activity, healthy diet score, coffee/tea intake, alcohol consumption, average noise level, PM2.5, accelerometer wear season, heart failure, dyslipidemia, hypertension, depression, and osteoarthritis.

§

Model 3 adjusted for covariates in model 2 along with BMI and waist circumference. Results are from Cox proportional hazards models. Follow-up time variable was in years, with two decimals.

There was evidence for nonlinearity, with participants with >60 min of sleep duration SD consistently having higher risk of diabetes across models (P nonlinearity ≤ 0.0544 in models 1 and 2, and P nonlinearity = 0.2151 in model 3) (Fig. 1). When we dichotomized sleep duration SD, compared with those with ≤60 min of sleep duration SD, participants with >60 min of sleep duration SD had 34% higher diabetes risk (95% CI 1.22, 1.47) in model 1 and 11% higher risk (95% CI 1.01, 1.22) in the fully adjusted model 3. Association patterns were similar when we further accounted for sleep-related covariates (data not shown), excluded diabetes cases diagnosed in the first 2 years of follow-up (Supplementary Table 3), or evaluated the pandemic period separately (Supplementary Table 4). While sleep duration SD was lower across weekdays (mean 1.02; SD 0.56) versus across 7 days (mean 1.10; SD 0.51), we observed somewhat stronger associations when evaluating sleep duration SD across weekdays in relation to diabetes risk (Supplementary Table 5). Lastly, PAR in model 1 was 8.3% (95% CI 5.7, 10.8), suggesting that, with age, sex, and race held constant, 8.3% of diabetes cases in the population could be potentially prevented by reducing sleep duration SD from >60 min to ≤60 min. The corresponding PAR (95% CI) was 1.1% (0.1, 2.1) in model 3.

Figure 1

Nonlinear associations between sleep duration SD and diabetes risk. Model 1 adjusted for age in months, sex, race. Model 3 adjusted for covariates in model 1 along with Townsend deprivation index, home area type, education, occupation/shift work, family history of diabetes, smoking, physical activity, healthy diet score, coffee/tea intake, alcohol consumption, average noise level, PM2.5, accelerometer wear season, heart failure, dyslipidemia, hypertension, depression, osteoarthritis, BMI, and waist circumference. Results are from Cox proportional hazards models with restricted cubic splines. We placed three knots at the 10th, 50th, and 90th percentiles of the distribution of sleep duration SD, measured in hours. These knots correspond to values of 0.45 h, 0.79 h, and 1.47 h, respectively.

Figure 1

Nonlinear associations between sleep duration SD and diabetes risk. Model 1 adjusted for age in months, sex, race. Model 3 adjusted for covariates in model 1 along with Townsend deprivation index, home area type, education, occupation/shift work, family history of diabetes, smoking, physical activity, healthy diet score, coffee/tea intake, alcohol consumption, average noise level, PM2.5, accelerometer wear season, heart failure, dyslipidemia, hypertension, depression, osteoarthritis, BMI, and waist circumference. Results are from Cox proportional hazards models with restricted cubic splines. We placed three knots at the 10th, 50th, and 90th percentiles of the distribution of sleep duration SD, measured in hours. These knots correspond to values of 0.45 h, 0.79 h, and 1.47 h, respectively.

Close modal

Gene-Sleep Interaction

Sleep duration SD was associated with diabetes risk irrespective of genetic risk for diabetes, although the association was stronger among individuals with lower diabetes PRS (P interaction in model 1: 0.0221) (Table 3). The HR (95% CI) for diabetes risk comparing >60 vs. ≤60 min of sleep duration SD was 1.83 (1.44, 2.31) in participants with low PRS, 1.40 (1.17, 1.67) in intermediate PRS, and 1.21 (1.06, 1.38) in high PRS. Sleep duration SD was not significantly associated with diabetes risk in individuals with intermediate or high PRS after additional covariate adjustment in model 3. However, we did not find evidence of effect modification by family history of diabetes (P interaction ≥ 0.1329) or the composite variable of diabetes PRS and family history (P interaction ≥ 0.2061). When evaluating the joint association between sleep duration SD and PRS, the highest diabetes risk was observed among participants with a high PRS and a sleep duration SD of >60 min compared with a low PRS and sleep duration SD of ≤60 (HR [95% CI] 3.31 [2.75, 3.98]) (Supplementary Fig. 5). No significant interaction on the additive scale between PRS and sleep duration SD on diabetes risk was observed (relative excess risk due to interaction comparing high versus low and intermediate PRS −0.23; 95% CI −0.59, 0.12; P = 0.1997).

Table 3

Effect heterogeneity analysis on the association between sleep duration SD (>60 vs. ≤60 min of sleep duration SD) and incident diabetes, n = 84,421

CasesModel 1*
HR (95% CI)
P interactionModel 3
HR (95% CI)
P interaction
Diabetes polygenic risk score tertiles   0.0221  0.0264 
 Low PRS: PRS ≤ −0.604 298 1.83 (1.44, 2.31)  1.47 (1.16, 1.86)  
 Intermediate PRS: −0.604 < PRS ≤ 0.225 543 1.40 (1.17, 1.67)  1.17 (0.97, 1.40)  
 High PRS: PRS > 0.225 1,032 1.21 (1.06, 1.38)  1.00 (0.88, 1.15)  
Family history of diabetes   0.3923  0.1329 
 No 1,334 1.30 (1.16, 1.46)  1.04 (0.93, 1.17)  
 Yes 724 1.40 (1.20, 1.63)  1.22 (1.04, 1.42)  
Composite diabetes PRS and family history§   0.2779  0.2061 
 Low PRS or without family history 1,452 1.40 (1.25, 1.56)  1.14 (1.02, 1.27)  
 High PRS and with family history 373 1.19 (0.95, 1.48)  0.98 (0.79, 1.23)  
Mean sleep duration, h   <0.0001  0.0009 
 <7 802 1.11 (0.96, 1.28)  0.96 (0.83, 1.11)  
 ≥7 and ≤8 844 1.41 (1.21, 1.64)  1.15 (0.99, 1.34)  
 >8 412 1.65 (1.33, 2.04)  1.35 (1.08, 1.68)  
CasesModel 1*
HR (95% CI)
P interactionModel 3
HR (95% CI)
P interaction
Diabetes polygenic risk score tertiles   0.0221  0.0264 
 Low PRS: PRS ≤ −0.604 298 1.83 (1.44, 2.31)  1.47 (1.16, 1.86)  
 Intermediate PRS: −0.604 < PRS ≤ 0.225 543 1.40 (1.17, 1.67)  1.17 (0.97, 1.40)  
 High PRS: PRS > 0.225 1,032 1.21 (1.06, 1.38)  1.00 (0.88, 1.15)  
Family history of diabetes   0.3923  0.1329 
 No 1,334 1.30 (1.16, 1.46)  1.04 (0.93, 1.17)  
 Yes 724 1.40 (1.20, 1.63)  1.22 (1.04, 1.42)  
Composite diabetes PRS and family history§   0.2779  0.2061 
 Low PRS or without family history 1,452 1.40 (1.25, 1.56)  1.14 (1.02, 1.27)  
 High PRS and with family history 373 1.19 (0.95, 1.48)  0.98 (0.79, 1.23)  
Mean sleep duration, h   <0.0001  0.0009 
 <7 802 1.11 (0.96, 1.28)  0.96 (0.83, 1.11)  
 ≥7 and ≤8 844 1.41 (1.21, 1.64)  1.15 (0.99, 1.34)  
 >8 412 1.65 (1.33, 2.04)  1.35 (1.08, 1.68)  
*

Model 1 adjusted for age, sex, and race.

Model 3 adjusted for covariates in model 1 along with Townsend deprivation index, home area type, education, occupation/shift work, family history of diabetes, smoking, physical activity, healthy diet score, coffee/tea intake, alcohol consumption, average noise level, PM2.5, accelerometer wear season, heart failure, dyslipidemia, hypertension, depression, osteoarthritis, BMI, and waist circumference.

Among 80,053 White participants with information on diabetes PRS. Models were further adjusted for the first 10 genetic principal components.

§

Among 78,756 White participants with information on diabetes PRS and family history. Models were further adjusted for the first 10 genetic principal components. Results are from Cox proportional hazards models. HRs are comparing participants with >60 min of sleep duration SD to those with ≤60 min of sleep duration SD. Continuous sleep duration SD was used when calculating P interactions.

Subgroup Analysis

The association between sleep duration SD and incident diabetes was stronger among participants with longer hours of mean sleep duration (P interaction ≤ 0.0009) (Table 3). The HR (95% CI) for diabetes risk comparing >60 vs. ≤60 min of sleep duration SD was 1.11 (0.96, 1.28) in participants with mean sleep duration <7 h, 1.41 (1.21, 1.64) in 7–8 h, and 1.65 (1.33, 2.04) in >8 h. We did not find significant differences in subgroup analyses by age, sex, race, Townsend deprivation index tertiles, BMI, insomnia, chronotype, or occupation/shift work (P interactions ≥ 0.0985) (Supplementary Table 6).

We found that irregular sleep duration, measured by 7-day SD in accelerometer-measured sleep duration, was nonlinearly associated with higher risk of developing diabetes. After accounting for comorbidities and adiposity, the association weakened, but remained apparent comparing participants with sleep duration SD of >60 vs. ≤60 min. Contrary to our initial hypothesis, we found that the association was stronger among individuals with low genetic risk for diabetes measured by diabetes PRS, although this gene-sleep interaction was not observed when genetic risk was assessed by family history or the composite measure. Further, the association was more pronounced among individuals with accelerometer-measured long sleep duration versus short sleep duration.

In the largest such study to date, we found that participants with greater sleep duration SD, particularly those with >60 min of sleep duration SD, are at higher risk of developing diabetes than those with lower sleep duration SD. This 60-min cutoff has been used as an empirical cutoff to define irregular sleep duration in other work (33). A 2022 systematic review identified 12 studies that reported inconsistent associations between different sleep variability measures (e.g., sleep regularity index, social jetlag, and sleep duration SD) and diabetes biomarkers, including HbA1c, insulin, and glucose (10). Another six studies, five of which were cross-sectional (10), evaluated the association between sleep variability and diabetes outcomes (total sample size 10,399). Three found positive associations between sleep irregularity and prevalent diabetes, while the remaining two reported null findings (10). The only prospective study found no association between sleep irregularity and increased diabetes incidence over 5.7 years of follow-up among 2,107 U.S. adults (aged 19–64 years), although a positive cross-sectional association was observed (11). Findings between the current study and the previous prospective study may differ because of variations in race, age, and follow-up periods. Notably, other prospective studies have reported associations between sleep irregularity and cardiometabolic outcomes other than diabetes, such as metabolic syndrome (8,10) and incident cardiovascular diseases (34). Nonetheless, a more recent panel review of existing evidence reached a consensus on the importance of sleep regularity for health, including metabolic health, although it was noted that high-quality, prospective studies were still needed to further characterize the associations (33).

Irregular sleep duration may give rise to diabetes through disrupting circadian rhythms in metabolic regulation and daily patterns of lifestyle behaviors (35). The circadian timing system coordinates various metabolic functions, including insulin secretion and glucose metabolism (2), via alignment with external cues (e.g., light exposure and meal timing). When sleep duration is irregular, these cues are likely to be irregular too, leading to unstable circadian entrainment. Through this mechanism, chronic irregular sleep duration could lead to reduced insulin sensitivity, disrupted glucose metabolism, and development of diabetes and other cardiometabolic outcomes (2,33). Additionally, irregular sleep duration is associated with other metabolically unhealthy sleep traits such as short/long sleep duration, poor sleep quality, and evening chronotype that have been shown to associate with worse glucose metabolism and diabetes risk (36). Adjustment for these sleep-related factors attenuated the association between sleep duration SD and diabetes risk in our analysis, but it did not fully account for it. Further, irregular sleep may interrupt behavioral rhythms and induce unhealthy habits, such as disrupted mealtime, irregular exercise timing (37), and late-night snacking (38), which are emerging risk factors for cardiometabolic disease. Other pathways through which irregular sleep duration may cause cardiometabolic outcomes are inflammation, gut dysbiosis, hypothalamic-pituitary-adrenal axis dysfunction, and autonomic dysfunction (35). Further research is warranted to understand the underlying mechanisms linking irregular sleep duration with diabetes risk (33).

Irregular sleep duration was associated with increased diabetes risk regardless of the diabetes PRS, suggesting that promoting regular sleep duration may benefit individuals with low, intermediate, or high genetic susceptibility for diabetes. In contrast to our hypothesis, we found stronger associations in individuals with low PRS, while individuals with intermediate or high PRS showed no significant associations after additionally adjusting for comorbidities and lifestyle factors. It is possible that the impact of sleep regularity on diabetes may be masked in the presence of a high genetic risk. However, it should be noted that such gene-sleep interaction effects were not consistently observed across different scales and gene-related variables. While the multiplicative interaction was observed for diabetes PRS, it was not for family history and the composite measure. Additionally, for diabetes PRS, we did not find evidence of an interaction on the additive scale. Similarly, a 2015 meta-analysis of 15 cohort studies did not identify a robust gene-sleep duration interaction on cardiometabolic traits (39). However, we were unable to identify studies on the interactions between genetic susceptibility and irregular sleep duration. We further found stronger sleep duration SD and diabetes association among participants with >8 h of average sleep duration. Longer sleep duration might reduce daylight exposure, which could, in turn, give rise to circadian disruption. To further evaluate the role of genetic risk, future studies could apply causal inference methodology considering risk factor variations across strata of genetic risk.

Our study has several key strengths. First, we utilized a large, population-based sample, which reduces sampling error. Second, we utilized sleep data that were objectively collected in participants’ usual environment, and used a validated method for identifying diabetes cases through medical records and subsequent clinical review. Third, our use of a prospective study design, in contrast to a cross-sectional approach, and careful adjustment for many important covariates provides enhanced causal insights into the association. Lastly, we employed a metric for sleep variability that is applicable in broader contexts and might allow for simpler interpretation compared with other measures. While multiple metrics exist and are often highly correlated, there is currently no consensus on a universal metric. However, compared with other metrics like sleep regularity index, sleep duration SD has more practical interpretations that may be converted to quantitative public health recommendations for improving sleep regularity (33,40).

Our study has some limitations. Most importantly, the time lag between covariate assessment and sleep duration SD measurements for some participants was large, ranging from 0 to 9 years (median 5 years). While this may not affect stable covariates like demographics or family history, it could bias lifestyle behaviors that can vary over time. To reduce potential residual confounding due to these time intervals, we updated the confounder information for participants who completed follow-up assessment visits after baseline (n = 9,542) by using the one conducted closest to the accelerometer study date. Further, sensitivity analyses suggest high stability for BMI values measured, on average, 4.2 years apart (r = 0.93). Another important limitation relates to the assessment of sleep duration SD based on 7-day sleep duration, which may not capture long-term habitual sleep patterns for some participants. Moreover, response rate in parental UKB cohort was ∼5.5% (14), and participants in the accelerometer study were selected based on a constrained random sampling approach, raising the potential of selection bias. However, risk factor associations found using UKB data were comparable to representative studies with conventional response rates (41). Lastly, our findings have limited generalizability, because of the relatively healthy, predominantly White study sample. Further research is essential to determine the applicability of our results to other populations.

In conclusion, our prospective study indicates that middle-aged to older adults with inconsistent sleep duration over the week have a heightened risk of developing diabetes relative to their counterparts with more consistent sleep patterns. This association persisted even after rigorous covariate adjustment, including obesity, comorbidities, family history of diabetes, and various lifestyle factors. Notably, individuals exhibiting a 1-week sleep duration variability exceeding 60 min were found to have consistently elevated diabetes risk compared with those with a variability of less than 60 min, suggesting a 1-h cutoff to define metabolically unhealthy irregular sleep duration. Further intervention studies and mechanistic research are needed to fully understand the biological and behavioral pathways linking irregular sleep duration to increased diabetes risk.

This article contains supplementary material online at https://doi.org/10.2337/figshare.26083861.

T.H. is currently affiliated with Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Baltimore, MD.

Acknowledgments. The authors express their gratitude to the participants and staff of the UKB study for their valuable contributions to research. During the course of preparing this work, the author(s) used OpenAI DALL-E for the purpose of making the image of “a person sleeping with an accelerometer” in the Graphical Abstract. Following the use of this tool/service, the author(s) formally reviewed the content for its accuracy and edited it as necessary.

Funding. This study was supported by the National Institutes of Health (grant number R01HL155395) and the UKB project 85501. S.K. was supported by the American Heart Association Postdoctoral Fellowship (https://doi.org/10.58275/AHA.24POST1188091.pc.gr.190780).

Duality of Interest. A.P. has received research funding from Versalux and Delos, and he is a director and founder of Circadian Health Innovations PTY LTD. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. T.H. supervised the work. S.K. and T.H. contributed to conception, study design, data acquisition, and analysis. S.K. wrote the first draft of the manuscript, and all authors edited, reviewed, participated in data interpretation, and approved the final version of the manuscript. S.K. and T.H. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented in abstract form at SLEEP 2023, Indianapolis, IN, 3–7 June 2023.

Handling Editors. The journal editors responsible for overseeing the review of the manuscript were Steven E. Kahn and Justin B. Echouffo-Tcheugui.

1.
International Diabetes Federation
.
IDF Diabetes Atlas
, 10th edition.
2021
. Accessed 1 February 2024. Available from https://diabetesatlas.org/atlas/tenth-edition/
2.
Stenvers
DJ
,
Scheer
FAJL
,
Schrauwen
P
,
la Fleur
SE
,
Kalsbeek
A
.
Circadian clocks and insulin resistance
.
Nat Rev Endocrinol
2019
;
15
:
75
89
3.
Jin
X
,
Chen
Y
,
Feng
H
, et al
.
Association of accelerometer-measured sleep duration and different intensities of physical activity with incident type 2 diabetes in a population-based cohort study
.
J Sport Health Sci
2024
;
13
:
222
232
4.
von Schantz
M
,
Ong
JC
,
Knutson
KL
.
Associations between sleep disturbances, diabetes and mortality in the UK Biobank cohort: a prospective population-based study
.
J Sleep Res
2021
;
30
:
e13392
5.
Vetter
C
,
Dashti
HS
,
Lane
JM
, et al
.
Night shift work, genetic risk, and type 2 diabetes in the UK Biobank
.
Diabetes Care
2018
;
41
:
762
769
6.
Morris
CJ
,
Yang
JN
,
Garcia
JI
, et al
.
Endogenous circadian system and circadian misalignment impact glucose tolerance via separate mechanisms in humans
.
Proc Natl Acad Sci U S A
2015
;
112
:
E2225
E2234
7.
Aguayo
GA
,
Pastore
J
,
Backes
A
, et al.;
Oriscav-Lux Study Group
.
Objective and subjective sleep measures are associated with HbA1c and insulin sensitivity in the general population: findings from the ORISCAV-LUX-2 study
.
Diabetes Metab
2022
;
48
:
101263
8.
Huang
T
,
Redline
S
.
Cross-sectional and prospective associations of actigraphy-assessed sleep regularity with metabolic abnormalities: the multi-ethnic study of atherosclerosis
.
Diabetes Care
2019
;
42
:
1422
1429
9.
Fischer
D
,
Klerman
EB
,
Phillips
AJK
.
Measuring sleep regularity: theoretical properties and practical usage of existing metrics
.
Sleep
2021
;
44
:
zsab103
10.
Zhu
B
,
Wang
Y
,
Yuan
J
, et al
.
Associations between sleep variability and cardiometabolic health: a systematic review
.
Sleep Med Rev
2022
;
66
:
101688
11.
Fritz
J
,
Phillips
AJK
,
Hunt
LC
, et al
.
Cross-sectional and prospective associations between sleep regularity and metabolic health in the Hispanic Community Health Study/Study of Latinos
.
Sleep
2021
;
44
:
zsaa218
12.
Patel
SR
,
Hayes
AL
,
Blackwell
T
, et al.;
Study of Osteoporotic Fractures (SOF) Research Groups
.
The association between sleep patterns and obesity in older adults
.
Int J Obes (Lond)
2014
;
38
:
1159
1164
13.
Dzierzewski
JM
,
Donovan
EK
,
Kay
DB
,
Sannes
TS
,
Bradbrook
KE
.
Sleep inconsistency and markers of inflammation
.
Front Neurol
2020
;
11
:
1042
14.
Sudlow
C
,
Gallacher
J
,
Allen
N
, et al
.
UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age
.
PLoS Med
2015
;
12
:
e1001779
15.
Doherty
A
,
Jackson
D
,
Hammerla
N
, et al
.
Large scale population assessment of physical activity using wrist worn accelerometers: the UK Biobank study
.
PLoS One
2017
;
12
:
e0169649
16.
Ladha
C
,
Ladha
K
,
Jackson
D
,
Olivier
P
.
Shaker table validation of OpenMovement AX3 accelerometer (Abstract)
. In
3rd International Conference on Ambulatory Monitoring of Physical Activity and Movement
. University of Massachusetts Amherst, 2013, p.
69
70
17.
Jones
SE
,
Lane
JM
,
Wood
AR
, et al
.
Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms
.
Nat Commun
2019
;
10
:
343
18.
Van Hees
VT
,
Fang
Z
,
Hua Zhao
J
, et al
.
GGIR: Raw Accelerometer Data Analysis
.
2023
.
Accessed 1 February 2024
. Available from https://CRAN.R-project.org/package=GGIR
19.
van Hees
VT
,
Sabia
S
,
Jones
SE
, et al
.
Estimating sleep parameters using an accelerometer without sleep diary
.
Sci Rep
2018
;
8
:
12975
20.
Migueles
JH
,
Rowlands
AV
,
Huber
F
,
Sabia
S
,
van Hees
VT
.
GGIR: a research community–driven open source R package for generating physical activity and sleep outcomes from multi-day raw accelerometer data
.
J Meas Phys Behav
2019
;
2
:
188
196
21.
Tange
O
.
Gnu parallel-the command-line power tool
.
Login USENIX Mag
2011
;
36
:
42
47
22.
UK Biobank
.
First occurrence of health outcomes defined by 3-character ICD10 code
2019
. Accessed 1 February 2024. Available from https://biobank.ndph.ox.ac.uk/ukb/refer.cgi?id=593
23.
Noordam
R
,
Läll
K
,
Smit
RAJ
, et al.;
Estonian Biobank Research Team
.
Stratification of type 2 diabetes by age of diagnosis in the UK Biobank reveals subgroup-specific genetic associations and causal risk profiles
.
Diabetes
2021
;
70
:
1816
1825
24.
Wang
W
,
Luo
J
,
Willems van Dijk
K
, et al
.
Assessment of the bi-directional relationship between blood mitochondrial DNA copy number and type 2 diabetes mellitus: a multivariable-adjusted regression and Mendelian randomisation study
.
Diabetologia
2022
;
65
:
1676
1686
25.
Li
G
,
Jankowich
MD
,
Lu
Y
,
Wu
L
,
Shao
L
,
Ke
C
.
Preserved ratio impaired spirometry, metabolomics, and the risk of type 2 diabetes
.
J Clin Endocrinol Metab
2023
;
108
:
e769
e778
26.
Bycroft
C
,
Freeman
C
,
Petkova
D
, et al
.
The UK Biobank resource with deep phenotyping and genomic data
.
Nature
2018
;
562
:
203
209
27.
Khera
AV
,
Chaffin
M
,
Zekavat
SM
, et al
.
Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction
.
Circulation
2019
;
139
:
1593
1602
28.
Thompson
DJ
,
Wells
D
,
Selzam
S
, et al
.
UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits. 1August 2022 [Preprint]
.
MedRxiv
:
2022.06.16.22276246
29.
Carr
MJ
,
Wright
AK
,
Leelarathna
L
, et al
.
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK
.
Lancet Diabetes Endocrinol
2021
;
9
:
413
415
30.
Cleveland
WS
.
Robust locally weighted regression and smoothing scatterplots
.
J Amer Stat Assoc
1979
;
74
:
829
836
31.
Ding
M
,
Ahmad
S
,
Qi
L
, et al
.
Additive and multiplicative interactions between genetic risk score and family history and lifestyle in relation to risk of type 2 diabetes
.
Am J Epidemiol
2020
;
189
:
445
460
32.
Rutten-Jacobs
LC
,
Larsson
SC
,
Malik
R
, et al
.
Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306 473 UK Biobank participants
.
BMJ
2018
;
363
:
k4168
33.
Sletten
TL
,
Weaver
MD
,
Foster
RG
, et al
.
The importance of sleep regularity: a consensus statement of the National Sleep Foundation sleep timing and variability panel
.
Sleep Health
2023
;
9
:
801
820
34.
Huang
T
,
Mariani
S
,
Redline
S
.
Sleep irregularity and risk of cardiovascular events: the multi-ethnic study of atherosclerosis
.
J Am Coll Cardiol
2020
;
75
:
991
999
35.
Zhang
C
,
Qin
G
.
Irregular sleep and cardiometabolic risk: clinical evidence and mechanisms
.
Front Cardiovasc Med
2023
;
10
:
1059257
36.
Kianersi
S
,
Liu
Y
,
Guasch-Ferré
M
, et al
.
Chronotype, unhealthy lifestyle, and diabetes risk in middle-aged U.S. women: a prospective cohort study
.
Ann Intern Med
2023
;
176
:
1330
1339
37.
Qian
J
,
Walkup
MP
,
Chen
S-H
, et al.;
Look AHEAD Research Group
.
Association of objectively measured timing of physical activity bouts with cardiovascular health in type 2 diabetes
.
Diabetes Care
2021
;
44
:
1046
1054
38.
Arble
DM
,
Bass
J
,
Laposky
AD
,
Vitaterna
MH
,
Turek
FW
.
Circadian timing of food intake contributes to weight gain
.
Obesity (Silver Spring)
2009
;
17
:
2100
2102
39.
Dashti
HS
,
Follis
JL
,
Smith
CE
, et al.;
CHARGE Nutrition Study Group
.
Gene-environment interactions of circadian-related genes for cardiometabolic traits
.
Diabetes Care
2015
;
38
:
1456
1466
40.
Bei
B
,
Wiley
JF
,
Trinder
J
,
Manber
R
.
Beyond the mean: a systematic review on the correlates of daily intraindividual variability of sleep/wake patterns
.
Sleep Med Rev
2016
;
28
:
108
124
41.
Batty
GD
,
Gale
CR
,
Kivimäki
M
,
Deary
IJ
,
Bell
S
.
Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis
.
BMJ
2020
;
368
:
m131
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.